Rethinking the antibody-dependent enhancement dengue hemorrhagic fever model

Oct 26, 2009

Research published this week in PLoS Medicine challenges the dogma of the antibody-dependent enhancement model (ADE) for the development of dengue hemorrhagic fever (DHF).

Dengue virus infection usually causes a severe 'flu like illness, although symptoms may be mild in young children. DHF, however, is a severe and sometimes fatal complication of infection that affects about half a million people every year. DHF patients usually fall into two groups; children and adults who become infected with a second dengue virus serotype after an initial ''primary'' dengue virus infection with a different serotype, and infants with primary dengue virus infections born to mothers who have some dengue virus immunity. The current model for development of DHF in infants around 6 months old is that anti-dengue virus antibodies transferred from a dengue-immune mother to her child somehow enhance dengue , resulting in more severe symptoms (the 'antibody-dependent enhancement' model).

A prospective nested case-control study of infant dengue carried out by Daniel Libraty (of the University of Massachusetts Medical School, Worcester, MA) and colleagues reveals that against dengue protect infants from the full spectrum of dengue disease. They also found that all infants with symptomatic dengue had antibodies with measurable ADE activity, but that there was no link between the amount of ADE activity and the development of DHF. They failed to find evidence supporting a role for the ADE model of development of DHF but did find that a higher weight-for-age was a risk factor for DHF.

The authors conclude that 'the results should encourage a rethinking or refinement of the currently promulgated ADE model for infant DHF, promote prospective studies of infant dengue and stimulate new directions of research into novel potential mechanisms for infant DHF'.

More information: Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Model. PLoS Med 6(10): e1000171. doi:10.1371/journal.pmed.1000171

Source: Public Library of Science (news : web)

Explore further: First controlled malaria infection trial in Africa paves way for drug and vaccine development

add to favorites email to friend print save as pdf

Related Stories

Lower transmission increases dengue deaths

Feb 04, 2008

A pair of researchers has answered a puzzle about why efforts to lower the transmission of dengue virus in Thailand have not resulted in decreases in the severe, life-threatening, form of the infection. In fact, it seems ...

Immune compound blocks virus' ability to hijack antibodies

Dec 12, 2007

Researchers at Washington University School of Medicine in St. Louis have shown that a controversial phenomenon known as antibody-dependent enhancement (ADE) of infection is suppressed by C1q, a blood-borne immune system ...

Study: Dengue fever is underreported

Oct 16, 2007

The American Society of Tropical Medicine and Hygiene is concerned about the U.S. blood supply due to underreporting of dengue fever.

Recommended for you

West African airline suspends flights amid Ebola (Update)

3 hours ago

(AP)—Police officers deployed to Liberia's international airport to ensure passengers are screened for Ebola symptoms as a major regional airline announced Tuesday it was suspending flights to the cities hardest hit by ...

$1,000 pill now hepatitis C treatment of choice

10 hours ago

(AP)—A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.

User comments : 0